Back To TopGet Opthea Updates

Shaping the Future of Wet AMD and Retinal Diseases

Our Vision

Advancing bold therapeutic innovation and inspiring transformation in the global retinal community.

Our Mission

Dedicated to improving and protecting vision in people with retinal diseases.

Company Overview

Opthea Limited (NASDAQ: OPT, ASX: OPT) is a global biopharmaceutical company aspiring to become the leader of therapeutic innovation in retinal diseases.

We started with a vision of the future, where the impact of retinal disease is reduced, and patients’ quality-of-life is enhanced. With people as our focus, we assembled a world-class team of ophthalmology experts in pursuit of breakthrough therapies. Together we focused on scientific innovation for those who suffer from retinal disease. Today, we are translating our discoveries into promising new medicines.

Company Overview Scientists

Management Team

Our executive leadership team has the experience, determination, and resources to make a positive and significant impact on the retinal community. We are building a culture of success that drives our transformation and leadership role as an important global ally in retinal care. Click the links below to learn more about the people who are leading our patient-focused mission.

Fred Guerard • PharmD, MS
Chief Executive Officer

Daniel Geffken
Chief Financial Officer ad interim

Megan Baldwin • PhD, MAICD
Founder, Chief Innovation Officer and Executive Director

Parisa Zamiri • MD, PhD
Chief Medical Officer

Mike Campbell
Chief Commercial Officer

Julie Clark • MD
Senior Vice President of Clinical Development

Fang Li • PhD
Senior Vice President Regulatory Affairs

Dayong Li • PhD
Senior Vice President, Biometrics

Jen Watts
Vice President Global Clinical Operations

Karen Adams • B.BBUS, CPA, GAICD, FCC GFIA
Vice President Finance and Company Secretary

Mark O’Neill
Vice President, Technical Operations

John Han • PharmD
Vice President, Medical Affairs

Anthony Bonifazio
Vice President, Market Access

Kevin Bitter
Vice President, Strategy & Corporate Development

Board of Directors

Our board believes in the promising future of our company and in the power of our transformational science and technology to establish a new standard-of-care for retinal diseases. Our board members bring the strategic expertise and necessary skills needed to help the company succeed, and collectively they provide important oversight and governance of the business.

Jeremy Levin

Jeremy Levin
Chairman of the Board

Megan Baldwin
Founder, Chief Innovation Officer and Executive Director

Lawrence Gozlan

Lawrence Gozlan
Non-Executive Director

Julia Haller

Julia Haller
Non-Executive Director

Susan Orr

Susan Orr
Non-Executive Director

Quinton Oswald

Quinton Oswald
Non-Executive Director

Anshul Thakral
Non-Executive Director

Sujal Shah
Non-Executive Director

Board of Directors Committee Composition

Board of Directors Composition

Board of Directors Committee Composition

Jeremy Levin

Jeremy Levin

  • Nominations & Governance Committee Member

Sajul Shah

Sujal Shah

  • Audit & Risk Committee Chair

Julia Haller

Julia Haller

  • Research & Development Committee Member

Lawrence Gozlan

Lawrence Gozlan

  • Nominations & Governance Committee Chair
  • Remuneration Committee Member

Susan Orr

Susan Orr

  • Research & Development Committee Chair
  • Audit & Risk Committee Member

Quinton Oswald

Quinton Oswald

  • Remuneration Committee Member
  • Research & Development Committee Member
  • Audit & Risk Committee Member

Anshul Thakral

Anshul Thakral

  • Remuneration Committee Chair
  • Nominations & Governance Committee Member
  • Research & Development Committee Member

Fred Guerard, CEO

Fred Guerard, CEO

  • Research & Development Committee – Ex Officio

Medical Advisory Board (MAB)

The members of the MAB advise the Company on opportunities to address the still unmet medical needs of patients with retinal diseases and help guide our development efforts.

Arshad M. Khanani • MD, MA, FASRS
Chief Medical Advisor
Chair, Opthea Medical Advisory Board

David S. Boyer • MD

Andrew Chang • AM, MBBS (Hons), PhD FRANZCO, FRACS

Frank G. Holz • MD, FEBO, FARVO

Anat Loewenstein • MD, MHA

Dante Pieramici • MD

Carl Regillo • MD, FASRS

Patricio G. Schlottmann • MD

Eric Souied  • MD, PhD

Tien Y Wong • MD, PhD

COAST and ShORe Steering Committee

The members of the COAST and ShORe Steering Committee provide expert advice on the Company’s Phase 3 clinical program in wet AMD.

David R.P. Almeida • MD, MBA, PhD, FRCSC, DABO

Margaret Chang • MD, MS

Gemmy Cheung • MBBS, FRCOphth, FAMS, MCI

David Eichenbaum • MD

Robyn Guymer • AM

Timothy L. Jackson • PhD, FRCOphth

Arshad M. Khanani • MD, MA, FASRS

David Lally • MD

Jason S. Slakter • MD

Veeral Sheth • MD, MBA, FACS

Adnan Tufail • MBBS, MD, FRCOphth

Charles C. Wykoff • MD, PhD

Parisa Zamiri • MD, PhD

Connect with Us

We appreciate your interest in Opthea.

Get Opthea Updates

Company news, pipeline updates, and more